Skip to main content
NCBI home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 May 26;8(2):E383. doi: 10.1007/BF02854909

Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse

Eric Peterson 1, S Michael Owens 1, Ralph L Henry 2,✉
PMCID: PMC3231570  PMID: 16796389

Abstract

Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with several candidates in preclinical and early clinical trials. Monoclonal antibodies can be designed that have customized affinity and specificity against drugs of abuse, and because antibodies can be designed in various forms, in vivo pharmacokinetic characteristics can be tailored to suit specific clinical applications (eg, long-acting for relapse prevention, or short-acting for overdose). Passive immunization with antibodies against drugs of abuse has several advantages over active immunization, but because large doses of monoclonal antibodies may be needed for each patient, efficient antibody production technology is essential. In this minireview we discuss some of the antibody forms that may be effective clinical treatments for drug abuse, as well as several current and emerging production systems that could bridge the gap from discovery to patient use.

Keywords: antibody therapy, antibody production

Full Text

The Full Text of this article is available as a PDF (357.4 KB).

References

  • 1.Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration (Herrlisheim) 2002;69:193–197. doi: 10.1159/000063617. [DOI] [PubMed] [Google Scholar]
  • 2.Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22:809–819. doi: 10.1016/S0192-0561(00)00042-4. [DOI] [PubMed] [Google Scholar]
  • 3.McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther. 1993;266:1439–1445. [PubMed] [Google Scholar]
  • 4.Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther. 1996;278:709–716. [PubMed] [Google Scholar]
  • 5.Byrnes-Blake KA, Laurenzana EM, Carroll FI, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol. 2003;461:119–128. doi: 10.1016/S0014-2999(03)01313-X. [DOI] [PubMed] [Google Scholar]
  • 6.McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol. 2002;13:465–473. doi: 10.1097/00008877-200209000-00019. [DOI] [PubMed] [Google Scholar]
  • 7.Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004;61:108–120. doi: 10.1002/ddr.10346. [DOI] [Google Scholar]
  • 8.Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352–1354. doi: 10.1038/2031352a0. [DOI] [PubMed] [Google Scholar]
  • 9.Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res. 1997;16:29–57. doi: 10.1007/BF02786322. [DOI] [PubMed] [Google Scholar]
  • 10.Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002;25:97–113. doi: 10.1385/IR:25:2:097. [DOI] [PubMed] [Google Scholar]
  • 11.Trang J. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo B, Mohler M, Gloff C, editors. Protein Pharmacokinetics and Metabolism. New York, NY: Plenum Press; 1992. pp. 223–270. [Google Scholar]
  • 12.Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:43–51. [PubMed] [Google Scholar]
  • 13.Stein KE. Immunogenicity: concepts/issues/concerns. Dev Biol (Basel) 2002;109:15–23. [PubMed] [Google Scholar]
  • 14.Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol. 1994;1:365–372. doi: 10.1128/cdli.1.4.365-372.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.King DJ, Byron OD, Mountain A, et al. Expression, purification and characterization of B72.3 Fv fragments. Biochem J. 1993;290:723–729. doi: 10.1042/bj2900723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kadokura H, Katzen F, Beckwith J. Protein disulfide bond formation in prokaryotes. Annu Rev Biochem. 2003;72:111–135. doi: 10.1146/annurev.biochem.72.121801.161459. [DOI] [PubMed] [Google Scholar]
  • 17.Simmons LC, Reilly D, Klimowski L, et al. Expression of full-length immunoglobulins inEscherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002;263:133–147. doi: 10.1016/S0022-1759(02)00036-4. [DOI] [PubMed] [Google Scholar]
  • 18.Venturi M, Seifert C, Hunte C. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol. 2002;315:1–8. doi: 10.1006/jmbi.2001.5221. [DOI] [PubMed] [Google Scholar]
  • 19.Cereghino GP, Cereghino JL, Ilgen C, Cregg JM. Production of recombinant proteins in fermenter cultures of the yeastPichia pastoris. Curr Opin Biotechnol. 2002;13:329–332. doi: 10.1016/S0958-1669(02)00330-0. [DOI] [PubMed] [Google Scholar]
  • 20.Peterson EC, Farrance C, Henry R, Owens SM. Engineering of a single chain antibody for treatment of methamphetamine abuse. 2004 Experimental Biology meeting abstracts [on CD-ROM] FASEB J. 2004;18:397.1–397.1. [Google Scholar]
  • 21.Damasceno LM, Pla I, Chang HJ, et al. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment inPichia pastoris. Protein Expr Purif. 2004;37:18–26. doi: 10.1016/j.pep.2004.03.019. [DOI] [PubMed] [Google Scholar]
  • 22.Joosten V, Lokman C, Van Den Hondel CA, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact. 2003;2:1–1. doi: 10.1186/1475-2859-2-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Murasugi A, Asami Y, Mera-Kikuchi Y. Production of recombinant human bile salt-stimulated lipase inPichia pastoris. Protein Expr Purif. 2001;23:282–288. doi: 10.1006/prep.2001.1509. [DOI] [PubMed] [Google Scholar]
  • 24.Ma JK, Drake PM, Christon P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 2003;4:794–805. doi: 10.1038/nrg1177. [DOI] [PubMed] [Google Scholar]
  • 25.Gleba Y, Klimyuk V, Marillonnet S. Magnifection—a new platform for expressing recombinant vaccines in plants. Vaccine. 2005;23:2042–2048. doi: 10.1016/j.vaccine.2005.01.006. [DOI] [PubMed] [Google Scholar]
  • 26.Gleba Y, Marillonnet S, Klimyuk V. Engineering viral expression vectors for plants: the ‘full virus’ and the ‘deconstructed virus’ strategies. Curr Opin Plant Biol. 2004;7:182–188. doi: 10.1016/j.pbi.2004.01.003. [DOI] [PubMed] [Google Scholar]
  • 27.Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y. Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol. 2005;23:718–723. doi: 10.1038/nbt1094. [DOI] [PubMed] [Google Scholar]
  • 28.Santi L, Giritch A, Roy CJ, et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA. 2006;103:861–866. doi: 10.1073/pnas.0510014103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gils M, Kandzia R, Marillonnet S, Klimyuk V, Gleba Y. High-yield production of authentic human growth hormone using a plant virus-based expression system. Plant Biotechnol J. 2005;3:613–620. doi: 10.1111/j.1467-7652.2005.00154.x. [DOI] [PubMed] [Google Scholar]
  • 30.Sharp JM, Doran PM. Characterization of monoclonal antibody fragments produced by plant cells. Biotechnol Bioeng. 2001;73:338–346. doi: 10.1002/bit.1067. [DOI] [PubMed] [Google Scholar]
  • 31.Derouazi M, Girard P, Van Tilborgh F, et al. Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng. 2004;87:537–545. doi: 10.1002/bit.20161. [DOI] [PubMed] [Google Scholar]
  • 32.Baldi L, Muller N, Picasso S, et al. Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog. 2005;21:148–153. doi: 10.1021/bp049830x. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES